Company Filing History:
2 out of 3,684 
1 out of 24 
1 out of 2,943 
Years Active: 2011-2022
Title: **David J Fontana: Innovator in Cancer Therapy**
Introduction
David J Fontana is a notable inventor hailing from Clyde Hill, WA, with a significant contribution to the field of cancer treatment. He holds four patents, showcasing his commitment to innovating methods for combating tumors effectively.
Latest Patents
Among his latest patents, one notable invention is related to the "Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors." This patent provides methods for clinical treatment of advanced solid tumors, combining anti-LAG-3 antibodies with anti-PD-1 antibodies to enhance therapeutic outcomes. Another significant patent he developed is titled "PD-L1 antagonist combination treatments," which details combination therapies involving an antagonist of the Programmed Death Ligand 1 receptor (PD-L1) alongside another therapeutic agent, aimed at improving cancer treatments.
Career Highlights
Throughout his career, David J Fontana has been associated with leading pharmaceutical companies, including Bristol-Myers Squibb Company and Archemix Corporation. His work in these renowned companies has allowed him to make substantial advancements in immuno-oncology, focusing on developing breakthrough therapies for cancer patients.
Collaborations
In his professional journey, he has collaborated with prominent figures in the field, such as Alan J Korman and Nils Lonberg. These collaborations have significantly contributed to the innovative developments in his research, driving forward the understanding and treatment of various cancers.
Conclusion
David J Fontana's inventions and patents reflect a passionate commitment to advancing cancer treatments. His work continues to pave the way for new therapies, offering hope to patients battling various forms of cancer. As he moves forward, his contributions to the scientific community are expected to have a lasting impact on the field of oncology.